Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
Overview
- Phase
- Not Applicable
- Intervention
- Truvada qd
- Conditions
- HIV
- Sponsor
- Emory University
- Enrollment
- 4
- Locations
- 2
- Primary Endpoint
- Count of Total Cells Obtained From Cervicovaginal Lavage Samples
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV infection.
Detailed Description
In this study, the investigator seeks to understand the immune cells in the cervical fluid of HIV-negative healthy female volunteers, and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV infection. Maraviroc works by preventing HIV from entering human immune cells by blocking a protein on the outside of these cells called the C-C chemokine receptor type 5 (CCR5) receptor. When maraviroc is bound to this protein, the virus cannot enter the cell. The investigator thinks that CCR5 antagonists could be particularly good drugs for HIV pre-exposure prophylaxis (PrEP) and could potentially be dosed in ways that are easier to take than the current drugs used for PrEP. In order to further evaluate this PrEP strategy, the investigator will first study the immune cells in the blood and genital tract of HIV-negative healthy female volunteers over the course of 3 months to see how these cells change over time and are affected by factors such as age, menstrual cycle, and genital infections. The amount of maraviroc compared with the drugs in the current drugs used for PrEP (tenofovir/ emtricitabine) in the blood and genital tract of HIV-negative healthy female volunteers before, during, and after they are given maraviroc versus tenofovir/ emtricitabine for 7 days will be measured. We will also study immune cells from the blood and genital tract from these women to see if maraviroc, tenofovir, or emtricitabine have an effect on these cells that would prevent them from becoming infected with HIV.
Investigators
Anandi Sheth
Assistant Professor
Emory University
Eligibility Criteria
Inclusion Criteria
- •Age 18-44 years
- •Must be biologically female (defined as sex at birth)
- •HIV negative women with at least one of the following risk factors in the past 5 years
- •Injection drug use or use of crack, cocaine, heroin, or methamphetamine
- •Diagnosed with a sexually transmitted infection
- •Unprotected sex with 3 or more men
- •Having sex for drugs, money, or shelter
- •Sex with a known HIV-positive man
- •Having a partner meeting any of the preceding criteria
- •Normal menses (within 22-35 day intervals) for at least 3 cycles
Exclusion Criteria
- •Male sex (defined as sex at birth)
- •Pregnant or breastfeeding
- •Current use of systemic hormonal contraception
- •Symptomatic vaginal infection or genital ulcer disease at screening or treatment for vaginal infection in the last two weeks
- •Active malignancy for which the participant is undergoing evaluation and/or treatment
- •Immunosuppressive medications (i.e, systemic steroids)
- •Any surgery in the preceding 2 months
Arms & Interventions
Truvada qd
Women will be assigned at random Truvada 1 tablet PO daily
Intervention: Truvada qd
Maraviroc 300 qd
Women will be assigned at random Maraviroc 300 mg PO daily
Intervention: Maraviroc 300 qd
Outcomes
Primary Outcomes
Count of Total Cells Obtained From Cervicovaginal Lavage Samples
Time Frame: Baseline, Day 7, Day 14, Day 21
The count of CCR5+CD4+ T cells in the genital tract, before participants began study treatment, after 7 days of treatment, and during the post-treatment drug elimination period. The precise role of CCR5+CD4+ T cells in the female genital tract is unknown, however, higher cell counts may suggest the potential for more HIV target cells in the genital tract.
Secondary Outcomes
- Steady-state Area Under the Plasma Concentration-time Curve of Study Drug(7 days)
- Steady-state Area Under the Female Genital Tract Concentration-time Curve of Study Drug(7 days)